A new trading day began on Friday, with Neumora Therapeutics Inc (NASDAQ: NMRA) stock price down -7.27% from the previous day of trading, before settling in for the closing price of $11.69. NMRA’s price has ranged from $8.33 to $21.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 57.09%. With a float of $53.81 million, this company’s outstanding shares have now reached $158.83 million.
Let’s determine the extent of company efficiency that accounts for 124 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Neumora Therapeutics Inc (NMRA) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Neumora Therapeutics Inc is 65.69%, while institutional ownership is 30.05%. The most recent insider transaction that took place on Oct 18 ’24, was worth 239,319. In this transaction Director of this company sold 14,049 shares at a rate of $17.03, taking the stock ownership to the 20,100 shares. Before that another transaction happened on Oct 17 ’24, when Company’s Director sold 7,739 for $17.01, making the entire transaction worth $131,643. This insider now owns 20,100 shares in total.
Neumora Therapeutics Inc (NMRA) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.71 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 57.09% per share during the next fiscal year.
Neumora Therapeutics Inc (NASDAQ: NMRA) Trading Performance Indicators
Here are Neumora Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 10.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.85, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.63 in one year’s time.
Technical Analysis of Neumora Therapeutics Inc (NMRA)
Looking closely at Neumora Therapeutics Inc (NASDAQ: NMRA), its last 5-days average volume was 1.3 million, which is a jump from its year-to-date volume of 0.73 million. As of the previous 9 days, the stock’s Stochastic %D was 12.88%. Additionally, its Average True Range was 1.03.
During the past 100 days, Neumora Therapeutics Inc’s (NMRA) raw stochastic average was set at 25.91%, which indicates a significant increase from 5.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 107.74% in the past 14 days, which was higher than the 70.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.10, while its 200-day Moving Average is $12.52. However, in the short run, Neumora Therapeutics Inc’s stock first resistance to watch stands at $11.49. Second resistance stands at $12.15. The third major resistance level sits at $12.52. If the price goes on to break the first support level at $10.46, it is likely to go to the next support level at $10.09. Should the price break the second support level, the third support level stands at $9.43.
Neumora Therapeutics Inc (NASDAQ: NMRA) Key Stats
With a market capitalization of 1.62 billion, the company has a total of 161,561K Shares Outstanding. Currently, annual sales are 0 K while annual income is -235,930 K. The company’s previous quarter sales were 0 K while its latest quarter income was -58,700 K.
